Posts With Tag biotech

Gilead Sciences, Inc. (GILD) files an 8-K report detailing significant events on October 6, 2025. Essential for investors and analysts tracking NASDAQ updates.

Explore Regeneron Pharmaceuticals' 8-K filing from October 6, 2025, detailing significant events, stock info, and investor insights.

Discover critical insights from Dexcom, Inc.'s 8-K filing on September 14, 2025, detailing significant events affecting their common stock.

Explore Gilead Sciences, Inc.'s 8-K report detailing significant corporate changes and events affecting investors as of August 7, 2025. Stay informed on GILD's latest developments.

Discover Amgen's impressive Q2 2025 results with $9.179B revenue and $1.432B net income. Learn why it's a buy for investors!

Explore Vertex Pharmaceuticals' impressive Q2 2025 financial performance, featuring $1B net income and rising revenues. A recommended BUY for investors!

Explore Amgen Inc.'s latest 8-K filing detailing common stock and senior notes. Key insights on financing and corporate strategy included.

Discover Gilead Sciences, Inc.'s latest 8-K filing revealing significant shareholder updates as of July 30, 2025. Stay informed on GILD stock and financial transparency.

Explore Vertex Pharmaceuticals Inc.'s recent 8-K filing detailing significant events on August 4, 2025. Key insights on common stock and financial disclosures included.

Explore Moderna's Q2 2025 financial report highlighting a net loss of $825M, cash decline, and deferred revenue growth. Investment recommendation: Hold.

Explore Regeneron Pharmaceuticals' Q2 2025 financial performance, highlighting $1.39B net income, key products, and ongoing challenges. Investors advised to hold.

Discover the latest 8-K filing by Moderna, Inc. (MRNA) on August 1, 2025. Learn about significant events impacting shareholders and stock performance.